Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg
Phase of Trial: Phase IV
Latest Information Update: 20 May 2017
At a glance
- Drugs Nelarabine (Primary)
- Indications Acute lymphoblastic leukaemia
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis
- 24 Apr 2017 Planned End Date changed from 18 Aug 2018 to 18 Oct 2017.
- 24 Apr 2017 Planned primary completion date changed from 18 Aug 2018 to 18 Oct 2017.
- 05 Apr 2017 Status changed from active, no longer recruiting to recruiting.